How does cost, potency, and bleeding risk affect which antiplatelet you choose P2Y12 inhibitors? How long after starting, do you feel comfortable stopping DAPT on a patient? How do you manage DAPT in patients who need anticoagulation?
Show notes, Transcript and References: https://www.coreimpodcast.com/2021/04/07/5-pearls-on-dual…platelet-therapy/ (https://w ... Show More
Jun 29
#211 Breaking Down MASLD vs. MASH and the MAESTRO-NASH & ESSENCE Trials: Beyond Journal Club Segment
MASLD affects nearly one in three adults worldwide, yet many patients remain undiagnosed until advanced fibrosis or cirrhosis develops. So, which patients should clinicians actually be screening? When is a FIB-4 enough, and when should we move to elastography or hepatology referr ... Show More
33m 40s
Jun 10
#209 Dialysis and Fluid Management: 5 Pearls Segment
Why is fluid management the most important part of dialysis care? This episode explores the fundamentals of hemodialysis, why ESKD patients have unique physiology, and how volume overload, not just hypertension, drives many complications. Learn practical pearls on dry weight, sod ... Show More
31m 54s
Jan 2025
Antiplatelets, Anticoagulants, and Thrombolytics
Send us Fan MailNinja Nerds!Welcome to the Ninja Nerd Podcast with Zach and Rob! In this episode, we explore Antiplatelets, Anticoagulants, and Thrombolytics, focusing on their mechanisms and clinical uses. Topics include the pharmacology of antiplatelet agents such as aspirin an ... Show More
47m 19s
Nov 2022
Anticoagulants, Thrombolytics, and Antiplatelet Agents
Send us Fan MailThis week, Rob and Zach will be talking about Anticoagulants, Thrombolytics, and Antiplatelet AgentsWe will be discussing the following topics within this episode on Anticoagulants, Thrombolytics, and Antiplatelet Agents!Hemostasis: Coagulation Cascade, Extrinsic ... Show More
1h 13m
Apr 2025
Ep 203 Intermediate Risk Pulmonary Embolism Risk Stratification, Management and Algorithm
How do you predict which intermediate-risk patients will suddenly deteriorate? What role do risk scores, biomarkers, imaging, and hemodynamics play in decision-making? Should these patients receive anticoagulation alone, or is thrombolysis warranted? When should you consider cath ... Show More
1h 35m
Nov 2023
12. DVT Prophylaxis In The Critically Ill
<p>Every time we admit or care for a critically ill patient, we must consider their risk for deep venous thrombosis, or DVT. Many of our patients are at higher risk for DVT than the general population, but anticoagulants are not wholly benign drugs. What do we do? How do we ... Show More
54m 30s
Dec 2023
Dec 01 2023 This Week in Cardiology
<p>More from AHA including SGLT2 inhibitors, blood transfusion after MI; cracks in the armor of Factor XI inhibitors; and renal denervation are the topics John Mandrola, MD, covers in this week's podcast.</p> <p><em>This podcast is intended for healthcare professionals only</em>. ... Show More
27m 48s
Jul 2022
156. Time is Tissue - An Approach to STEMI
Send us Fan MailIn this high yield episode, we review the clinical presentation, up front investigations, immediate and long-term management of patients who present with STEMIs - one of the 5 causes of life-threatening chest pain. Our medicine minute reviews the PLATO trial, whic ... Show More
20m 7s